{"id":4875,"date":"2025-03-25T13:51:20","date_gmt":"2025-03-25T13:51:20","guid":{"rendered":"https:\/\/www.nordicbioscience.com\/?post_type=biomarker-solution&p=4875"},"modified":"2025-06-01T13:30:33","modified_gmt":"2025-06-01T13:30:33","slug":"respiratory-diseases","status":"publish","type":"biomarker-solution","link":"https:\/\/www.nordicbioscience.com\/biomarker-solution\/respiratory-diseases\/","title":{"rendered":"Respiratory Diseases"},"content":{"rendered":"
\n
\n
\n

Biomarkers for Respiratory Diseases <\/h1>\n

We provide a comprehensive range of Nordic biomarkers for assessing respiratory diseases, including mode-of-action biomarkers for COPD, pulmonary fibrosis, IPF, and other chronic respiratory diseases. We also support companies in optimizing their biomarker strategies to maximize the value and impact of their pulmonary pipeline.<\/p>\n

\n \n Browse respiratory biomarkers \n \n <\/svg>\n \n <\/a>\n <\/div>\n <\/article>\n <\/div>\n<\/section>\n\n\n\n\n
\n \n
\n
\n
\n
\n

Biomarkers for chronic respiratory diseases<\/h2>\n \n\n <\/div>\n
\n

Chronic respiratory diseases such as COPD are highly heterogeneous and the traditional \u201cone size fits all\u201d treatment approach has largely failed. However, by stratifying patients based on subtypes using biomarkers, there is a potential to enhance the success rate in clinical trials by recruiting patients with the greatest likelihood of treatment response.<\/p>\n <\/div>\n

\n

Publications<\/h3>\n